This phase 2a study evaluating 2 doses (25 and 100 mg TID) of olorinab during an 8-week period demonstrated that this highly selective, peripherally acting, full agonist of CB2 was generally safe and well tolerated in patients with quiescent to mildly active CD. The gene discussed is CNR2; the disease is Cowden disease.